Piracetam and event-related potentials in dyslexic males

Piracetam in developmental reading disorders: A review

This paper reviews the studies that have examined piracetam, the first of the nootropic drugs, as a treatment for developmental reading disorder. In various studies, 751 children have completed treatment in controlled double-blind trials using standardised tests of reading as outcome measures. Quantitative and qualitative review suggests that the findings are best interpreted as showing a statistical superiority of piracetam over placebo. Mechanism of action and clinical significance are discussed. The effect size is modest, but the drug is well tolerated and the balance of benefit over hazard is encouraging for future use.

The nootropic concept and dyslexia

A review is presented of controlled studies using intensive teaching intervention to improve dyslexics' reading ability. The results of eight controlled studies reveal only one showing the superiority of teaching. Taking this as a background, the work on Nootropics is reviewed. Both animal and clinical work with Piracetam (the first of the Nootropics) seems to indicate that this medication lacks significant or serious side effects and appears to promote memory and learning. Many double-blind studies of Piracetam have now been conducted on dyslexic children. These studies suggest that Piracetam improves the reading ability of dyslexics. In addition electrophysiological studies support the notion that Piracetam may be "left hemisphere active." Such encouraging trends will doubtless lead to further research in this interesting area.